CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,428 | -10.4% | 2,521 | +10.8% | 0.01% | -16.7% |
| Q2 2023 | $127,775 | +76.5% | 2,276 | +42.2% | 0.01% | +50.0% |
| Q1 2023 | $72,413 | +6.8% | 1,601 | -4.8% | 0.00% | +33.3% |
| Q4 2022 | $67,784 | -0.3% | 1,681 | +60.4% | 0.00% | 0.0% |
| Q3 2022 | $68,000 | -20.9% | 1,048 | -25.6% | 0.00% | 0.0% |
| Q2 2022 | $86,000 | -30.6% | 1,409 | -28.7% | 0.00% | 0.0% |
| Q1 2022 | $124,000 | -19.5% | 1,975 | +1.1% | 0.00% | -40.0% |
| Q4 2021 | $154,000 | +71.1% | 1,954 | +142.1% | 0.01% | 0.0% |
| Q3 2021 | $90,000 | -11.8% | 807 | +28.7% | 0.01% | 0.0% |
| Q2 2021 | $102,000 | – | 627 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |